Short-course Rifapentine-based Treatment for Drug-sensitive Pulmonary Tuberculosis in Adults
Led by Huashan Hospital · Updated on 2023-12-11
2442
Participants Needed
6
Research Sites
160 weeks
Total Duration
AI-Summary
What This Trial Is About
Tuberculosis TB remains a leading infectious disease worldwide, with treatment challenges including poor adherence to long and complex regimens. Researchers are evaluating high-dose rifapentine regimens to treat rifampicin-sensitive pulmonary tuberculosis with the aim of shortening treatment duration and reducing side effects and economic burden. This multicenter, prospective, randomized controlled study focuses on assessing the safety, effectiveness, and pharmacokineticspharmacodynamics of these regimens compared to the standard treatment.
The study includes four treatment groups three experimental groups receiving rifapentine at doses of 10mgkg, 15mgkg, or 20mgkg combined with isoniazid, pyrazinamide, and moxifloxacin during an 8-week intensive phase, followed by a continuation phase of 9 weeks with rifapentine, isoniazid, and moxifloxacin and one comparator group receiving the World Health Organizations standard 26-week regimen with rifampicin, isoniazid, pyrazinamide, and ethambutol. The continuation phase may be extended up to 18 weeks if certain treatment response criteria are not met.
Participants will be monitored through treatment and follow-up lasting up to 108 weeks after randomization. Researchers will evaluate treatment success rates, culture conversion at various time points, relapse rates, and adverse events throughout the study period. Safety assessments will include laboratory tests and clinical evaluations to monitor tolerability and drug effects, ensuring thorough observation during and after treatment completion.
CONDITIONS
Brief Title
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
Research Team
F
Feng Sun, Dr.
Y
Yang Li, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with smear-positive pulmonary tuberculosis sensitive to rifampicin
Willing to provide signed informed consent or parental consent and participant assent
Non-menopausal women must agree to use effective contraception during treatment
You will not qualify if you...
Presence of combined extrapulmonary tuberculosis
Extensive lung lesions (disease extent >50% or cavity size >4cm)
Known resistance to rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones
Alcohol abuse (more than 64g ethanol/day for males, 42g for females)
Hemoglobin less than 70g/L or platelet count less than 100x10^9/L
Impaired liver function (hepatic encephalopathy, ascites, elevated bilirubin or liver enzymes)
Blood creatinine more than 1.5 times the upper limit of normal
More than five days of systemic treatment with specified anti-TB drugs within 6 months before study
Known prolonged QT syndrome
Current or planned use of certain HIV or cardiac medications
Allergy or intolerance to study medications
AIDS patients
Pregnant or breastfeeding women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 17 to 26 weeks
Participants receive one of several drug regimens for drug-sensitive tuberculosis. Treatment includes an intensive phase of 8 weeks followed by a continuation phase of 9 weeks, with possible extension up to 18 weeks depending on smear conversion and cavity closure.
Weekly visits during intensive phase and biweekly visits during continuation phase
Follow-up
Duration - Up to 82 to 91 weeks after treatment ends
Participants are monitored after completing treatment to assess treatment success, safety, and relapse rates.
Periodic visits during follow-up phase
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Study of 18F-Fibroblast Activation Protein Inhibitor 18F-FAPI-74 PETCT Scans in Adults with Pulmonary Tuberculosis to Detect Lung Fibrosis
Screening for Tuberculosis in High-Risk Groups Living in Barcelona
Double-blind, Randomized, Placebo-controlled Trial of 40 mg Atorvastatin to Reduce Lung Inflammation After Tuberculosis Treatment in Adults With and Without HIV
Monitoring Tuberculosis Treatment Using Blood Tuberculosis DNA Levels
A Study on Mycobacterium Tuberculosis Cell-free DNA to Track Treatment Response
Evaluating Doxycycline to Prevent Lung Scarring and Improve Breathing in Adults with Advanced Pulmonary Tuberculosis in a Double-Blind Randomized Trial
Digital Health Education and Reminder Intervention to Improve Tuberculosis Preventive Therapy Among Close Contacts in South Ethiopia
Individualized Dosing Using Model-Informed Precision Dosing for Adults with Pulmonary Tuberculosis
Evaluation of Fibroblast Activating Protein FAP PETCT Imaging in Adults with Pulmonary Tuberculosis to Assess Lung Fibrosis and Damage
Phase 1 Study to Evaluate Safety and Immune Response of the TB Vaccine QTP101 ID93GLA-SE in Adults Aged 55 to 74 Who Have Been Vaccinated with BCG
Short-course Rifapentine-based Treatment for Drug-sensitive Pulmonary Tuberculosis in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.